Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19

OBJECTIVES: The oral antiviral drugs nirmatrelvir/ritonavir (NMV/r) and molnupiravir have been approved for early outpatient treatment of COVID-19 to prevent severe disease. Ritonavir, contained in NMV/r, is known to have significant drug-drug interactions (DDI) with several drugs frequently used by...

Descripción completa

Detalles Bibliográficos
Autor principal: Larsen, Carsten Schade
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258411/
https://www.ncbi.nlm.nih.gov/pubmed/35803465
http://dx.doi.org/10.1016/j.ijid.2022.06.059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258411/
https://www.ncbi.nlm.nih.gov/pubmed/35803465
http://dx.doi.org/10.1016/j.ijid.2022.06.059

Ejemplares similares